Clinical trials: Psoriasis Arthritis
Psoriatic Arthritis
A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis
This is a study to demonstrate the clinical efficacy, safety and tolerability of bimekizumab administered subcutaneously (sc) compared with placebo in the treatment of subjects with active Psoriatic Arthritis (PsA).
- Trial name
- BE OPTIMAL (NCT03895203)
- Testing
- Bimekizumab, Adalimumab
- Where
- 136 sites in United States, Australia and 12 more
- Volunteers
- 852 people
- Sponsor
- UCB Biopharma SRL
Psoriatic Arthritis, Axial Spondyloarthritis
Study of Efficacy and Safety of Secukinumab in Psoriatic Arthritis and Axial Spondyloarthritis Patients With Active Enthesitis Including One Achilles Tendon Site
The purpose of this study was to demonstrate efficacy, including effects on inflammation by magnetic resonance imaging (MRI) assessments, of secukinumab on Achilles tendon enthesitis for up to 1 year with a primary focus at Week…
- Conditions
- Psoriatic Arthritis, Axial Spondyloarthritis, Enthesitis
- Trial name
- ACHILLES (NCT02771210)
- Testing
- Secukinumab
- Where
- 55 sites in Bulgaria, Czechia and 6 more
- Volunteers
- 204 people
- Sponsor
- Novartis Pharmaceuticals
Arthritis, Psoriatic
PsA Treatment With hOKT3γ1 (Ala-Ala)
hOKT3gamma1 (Ala-Ala) is a man-made antibody that is commonly used to prevent organ rejection. The purpose of this study is to determine whether hOKT3gamma1 (Ala-Ala) is safe and effective in psoriatic arthritis patients who are…
- Trial name
- PART (NCT00239720)
- Testing
- hOKT3gamma1(Ala-Ala)
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Psoriatic Arthritis
Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis
This study was designed as a 3-year extension to the phase III core study CAIN457F2306. It aimed to provide continuous treatment with secukinumab in pre-filled syringes (PFS) for subjects who completed the core study…
- Trial name
- FUTURE 1 ext (NCT01892436)
- Testing
- Secukinumab
- Where
- 94 sites in United States, Argentina and 16 more
- Volunteers
- 460 people
- Sponsor
- Novartis Pharmaceuticals
Arthritis, Psoriatic
Open-Label Extension Study Of Tofacitinib In Psoriatic Arthritis
This is a Phase 3, long-term open-label extension study to evaluate the safety, tolerability and efficacy of tofacitinib in subjects with active PsA who have previously participated in randomized studies of tofacitinib for this…
- Trial name
- OPAL BALANCE (NCT01976364)
- Testing
- Tofacitinib, Methotrexate
- Where
- 153 sites in United States, Australia and 14 more
- Volunteers
- 686 people
- Sponsor
- Pfizer
Crohn's Disease, Rheumatoid Arthritis
An ObserVatIonal STudy of the Effectiveness of AdaLimumab on Health and Disability Outcomes in New Zealand Patients With Immune-Mediated InflammaTorY Diseases (VITALITY)
For public health purposes disability is becoming increasingly important as an outcome measure. Despite this, there are few data on the effectiveness of adalimumab on disability outcomes in patients with immune-mediated…
- Conditions
- Crohn's Disease, Rheumatoid Arthritis, Psoriasis
- Trial name
- VITALITY (NCT02451839)
- Volunteers
- 168 people
- Sponsor
- AbbVie
Arthritis, Psoriatic
A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti -Tumor Necrosis Factor (TNF) Alpha Agent(s)
The primary purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active Psoriatic Arthritis (PsA) by assessing the reduction in signs and symptoms of PsA.
- Trial name
- Discover-1 (NCT03162796)
- Testing
- Guselkumab
- Where
- 95 sites in United States, Australia and 11 more
- Volunteers
- 383 people
- Sponsor
- Janssen Research & Development, LLC
Psoriatic Arthritis
Study To Evaluate The Impact Of Anti-Cyclic Citrullinated Peptide(Anti-CCP) For Management With Enbrel In Patients With Psoriatic Arthritis(PsA)
This study is to evaluate the local data in Iraqi patients with psoriatic arthritis on Enbrel treatment with positive Anti-Cyclic Citrullinated Peptide using data from the Rheumatologist in Baghdad Teaching Hospital registry.
- Trial name
- NCT04428502
- Testing
- Enbrel
- Where
- Iraq
- Volunteers
- 127 people
- Sponsor
- Pfizer
Psoriatic Arthritis
Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)
The purpose of this study is to determine whether apremilast is safe and effective in the treatment of patients with psoriatic arthritis who have not been previously treated with DMARDs.
- Trial name
- PALACE4 (NCT01307423)
- Testing
- Apremilast 20mg, Apremilast 30mg
- Where
- 118 sites in United States, Australia and 16 more
- Volunteers
- 529 people
- Sponsor
- Amgen
Psoriatic Arthritis
Efficacy And Safety Of Tofacitinib In Chinese Subjects With Active Psoriatic Arthritis
This is a 6 month study investigating the effectiveness and safety of tofacitinib in treating signs and symptoms and improving physical function in Chinese patients with active psoriatic arthritis and had inadequate response to a…
- Trial name
- NCT03486457
- Testing
- Tofacitinib
- Where
- 38 sites in China
- Volunteers
- 204 people
- Sponsor
- Pfizer
Psoriatic Arthritis
Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis
This study was to provide 24 - 52 week efficacy, safety and tolerability data to support the registration of the secukinumab (AIN457) prefilled syringe (PFS) for subcutaneous self administration in subjects with active PsA…
- Trial name
- FUTURE 2 (NCT01752634)
- Testing
- Secukinumab (AIN457)
- Where
- 76 sites in United States, Australia and 9 more
- Volunteers
- 397 people
- Sponsor
- Novartis Pharmaceuticals
Psoriatic Arthritis
Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Are Naive to Biologic DMARD Therapy
The primary objective of this study is to evaluate the effect of filgotinib compared to placebo as assessed by the American College of Rheumatology 20% improvement (ACR20) response in participants with active psoriatic arthritis…
- Trial name
- PENGUIN 1 (NCT04115748)
- Testing
- Filgotinib, Adalimumab
- Where
- 74 sites in United States, Australia and 11 more
- Volunteers
- 67 people
- Sponsor
- Gilead Sciences
Rheumatoid Arthritis, Psoriatic Arthritis
Study to Characterize Demographics, Compliance, Tolerability and Safety in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Prescribed Adalimumab (Humira®) as Part of Routine Clinical Care
The primary objective of this post-marketing observational study was to obtain data on the characteristics (patient age/gender; disease type, severity and duration; disease specific treatment history; current concomitant…
- Conditions
- Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis
- Trial name
- NCT01163916
- Where
- 43 sites in Russia
- Volunteers
- 252 people
- Sponsor
- Abbott
Arthritis, Rheumatoid, Spondylitis, Ankylosing
Post Marketing Surveillance Study of Remicade in Patients With Chronic Inflammatory Diseases (P04840)
This study will be performed to evaluate and document the safety and efficacy of infliximab (Remicade®) in the treatment of chronic inflammatory diseases in big cohorts in the daily routine practice of rheumatologists…
- Conditions
- Arthritis, Rheumatoid, Spondylitis, Ankylosing, Arthritis, Psoriatic, Psoriasis
- Trial name
- REMission (NCT00727298)
- Testing
- Infliximab
- Volunteers
- 4,485 people
- Sponsor
- Merck Sharp & Dohme LLC
Psoriatic Arthritis
A Study to Investigate Safety With Risankizumab in Psoriatic Arthritis Subjects Who Have Completed Week 24 Visit of Study M16-002 (NCT02719171)
This is an open-label extension (OLE) study to assess the efficacy, safety and tolerability of risankizumab in participants with psoriatic arthritis (PsA).
- Trial name
- NCT02986373
- Testing
- risankizumab
- Volunteers
- 145 people
- Sponsor
- AbbVie
Psoriatic Arthritis
Multicentre ObservatioNal Initiative in Treat to Target Outcomes in Psoriatic Arthritis
MONITOR is a cohort study recruiting patients with a new diagnosis of psoriatic arthritis (PsA) which will establish outcomes using a pragmatic feasible 'treat to target' approach in a real-life clinic population.
- Trial name
- MONITOR (NCT03531073)
- Testing
- Methotrexate
- Where
- United Kingdom
- Volunteers
- 446 people
- Sponsor
- University of Oxford
Psoriatic Arthritis
Study of Efficacy, Safety and Effect on Radiographic Progression of Brodalumab in Subjects With Psoriatic Arthritis
The primary objective of this study is to evaluate the efficacy of brodalumab, compared to placebo, in subjects with psoriatic arthritis.
- Trial name
- AMVISION-1 (NCT02029495)
- Testing
- 210 mg brodalumab, 140 mg brodalumab
- Where
- 152 sites in United States, Belgium and 15 more
- Volunteers
- 478 people
- Sponsor
- Bausch Health Americas, Inc.
Axial Spondyloarthritis (AxSpA), Non-radiographic Evidence-AxSpA
A Multicener, Postmarketing Study Evaluating the Transfer of Cimzia From the Mother to the Infant Via the Placenta
The primary purpose is to assess whether there is transfer of Certolizumab Pegol (CZP) from pregnant women receiving treatment with Cimzia® across the placenta to infants by evaluating the concentration of CZP in the plasma of…
- Conditions
- Axial Spondyloarthritis (AxSpA), Non-radiographic Evidence-AxSpA, Ankylosing Spondylitis, Crohn's Disease
- Trial name
- CRIB (NCT02019602)
- Testing
- Blood sampling from mother, Blood sampling from infant, Blood sampling from umbilical cord
- Where
- 8 sites in United States, France and 2 more
- Volunteers
- 37 people
- Sponsor
- UCB BIOSCIENCES, Inc.